Edesa Intangible Assets from 2010 to 2026

EDSA Stock  USD 1.07  0.02  1.90%   
Edesa Biotech's Intangible Assets are increasing over the years with slightly volatile fluctuation. Intangible Assets are expected to dwindle to about 1.5 M. Intangible Assets is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. View All Fundamentals
 
Intangible Assets  
First Reported
2010-06-30
Previous Quarter
M
Current Value
M
Quarterly Volatility
1.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Edesa Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edesa Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 127.3 K, Interest Expense of 993.4 K or Selling General Administrative of 3.7 M, as well as many indicators such as Price To Sales Ratio of 2.7 K, Dividend Yield of 0.0 or PTB Ratio of 115. Edesa financial statements analysis is a perfect complement when working with Edesa Biotech Valuation or Volatility modules.
  
Build AI portfolio with Edesa Stock
Check out the analysis of Edesa Biotech Correlation against competitors.
For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.
Analyzing Edesa Biotech's Intangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Intangible Assets has evolved provides context for assessing Edesa Biotech's current valuation and future prospects.

Latest Edesa Biotech's Intangible Assets Growth Pattern

Below is the plot of the Intangible Assets of Edesa Biotech over the last few years. It is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. Edesa Biotech's Intangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edesa Biotech's overall financial position and show how it may be relating to other accounts over time.
Intangible Assets10 Years Trend
Slightly volatile
   Intangible Assets   
       Timeline  

Edesa Intangible Assets Regression Statistics

Arithmetic Mean1,915,483
Geometric Mean1,408,360
Coefficient Of Variation45.76
Mean Deviation665,635
Median2,281,192
Standard Deviation876,484
Sample Variance768.2B
Range2.4M
R-Value0.46
Mean Square Error644.1B
R-Squared0.21
Significance0.06
Slope80,294
Total Sum of Squares12.3T

Edesa Intangible Assets History

20261.5 M
20252.3 M
2024M
20232.1 M
20222.2 M
20212.3 M
20202.4 M

About Edesa Biotech Financial Statements

Edesa Biotech stakeholders use historical fundamental indicators, such as Edesa Biotech's Intangible Assets, to determine how well the company is positioned to perform in the future. Although Edesa Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Edesa Biotech's assets and liabilities are reflected in the revenues and expenses on Edesa Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Edesa Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Intangible Assets2.3 M1.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:
Check out the analysis of Edesa Biotech Correlation against competitors.
For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. Projected growth potential of Edesa fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Edesa Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.27)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.57)
Return On Equity
(1.00)
Investors evaluate Edesa Biotech using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Edesa Biotech's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Edesa Biotech's market price to deviate significantly from intrinsic value.
It's important to distinguish between Edesa Biotech's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Edesa Biotech should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Edesa Biotech's market price signifies the transaction level at which participants voluntarily complete trades.